NCT06361212

Ethoximod Pharmacokinetics In Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Ethoximod in Healthy Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Longevity Inc. · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects. The main questions it arms to answer are: 1. to evaluate the safety and tolerance of Ethoximod in healthy subjects after single or repeated doses. 2. to assess the pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects after single or repeated doses. 3. to evaluate of the effect of food on the pharmacokinetics of Ethoximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Ethoximod	Ethoximod is a S1P1 modulator.

Timeline

• Start date: 2022-09-01
• Primary completion: 2022-09-20
• Completion: 2024-01-12
• First posted: 2024-04-11
• Last updated: 2024-04-11

Locations

1 site across 1 country: China